Clinical Trials Resource Center

Lymphoma, B-Cell

February 3, 2014

Janssen has issued positive results of a phase II study of siltuximab for the treatment of Multicentric Castleman’s Disease (MCD) in subjects who are HIV-negative and human herpes virus-8 (HHV-8)-negative. The multi-national, randomized, double-blind, placebo-controlled study involved 79 subjects randomized 2:1 to receive either siltuximab plus best supportive care (BSC) or placebo plus BSC until protocol-defined treatment failure, after which patients taking the placebo could cross over to un-blinded siltuximab. Half of the patients on placebo (13 out of 26) crossed over to siltuximab. The study found more than one-third of patients in the siltuximab arm had a durable tumor and symptomatic response to treatment, compared to none of the patients who received placebo plus BSC (34% v. 0%). In looking at the response rate to treat MCD-related symptoms, 25% of patients who received siltuximab plus BSC had durable complete symptom resolution, defined as 100% reduction of baseline overall symptom scores for at least 18 weeks, compared to none of the patients who received placebo plus BSC. These data supported the recent regulatory filings of siltuximab in the U.S. and E.U.

December 17, 2012

Senesco Technologies released interim results from an ongoing phase Ib/IIa trial of SNS01-T for the treatment of multiple myeloma, mantle cell (MCL) and B-cell lymphoma (DLBCL). This open-label, multiple-dose, dose-escalation study enrolled two patients so far with relapsed or refractory multiple myeloma. Subjects received SNS01-T or 0.0125mg/kg per dose intravenously, while the next three arms will receive SNS01-T or 0.05mg/kg, 0.2mg/kg or 0.375mg/kg per dose intravenously. Blood levels of monoclonal (M)-protein were measured using serum protein electrophoresis. Data showed patients 41-002 and 42-002 in cohort 1, serum levels of M-protein remained within 25% of the baseline values (3.60g/dL, 3.0g/dL respectively) at weeks three (3.90g/dL, 2.8g/dL) and six (4.20g/dL, 2.8g/dL), stable disease. For patient 42-002, M-protein stayed within 25% of baseline at week 10 (3.2g/dL)—four weeks after the end of treatment. M-protein levels for patient 43-001 increased from baseline to week three by 26% and from baseline to week six by 30%. Indicative of the partial disappearance of cancer cells, the plasma cell levels for patients 41-002 and 42-002 declined from 70% to 50% and from 50% to 15%, respectively. Plasma cell levels for patient 43-001 increased from 70% at baseline to 97% at end of treatment. Based on these data, Senesco Technologies will continue to dose patients in the other three arms.

May 23, 2011

CureTech released preliminary results from a phase II trial of CT-011 for Diffuse Large B Cell Lymphoma (DLBCL). This open label trial enrolled 72 subjects with DLBCL following autologous stem cell transplantation. The subjects received three intravenous infusions of 1.5 mg/kg of CT-011 every six weeks and were then followed for 13 months. The primary endpoint was progression-free survival within 16 months following the first CT-011 treatment compared to historical control. Preliminary analyses indicated that 70% of the subjects treated with CT-011 were progression-free at the end of the follow-up period, as compared to 47% in the historical control. In addition, 84% of the subjects treated with CT-011 were alive by the end of the follow-up period, compared to 62% in the historical control.

December 1, 2008

Transgene issued positive interim data from a phase II trial of TG1042, an immunotherapy for the treatment of cutaneous B-cell lymphoma (CBCL). This non-controlled, open label, two stage trial is underway in the US, France and Switzerland. Stage 1 enrolled 13 subjects who were treated with intra-lesional injections of 5 x 1010 viral particles of TG1042 per lesion, three times a month, for up to four months. The primary objective, to reach eight responding patients out of 13, was reached. Out of the 12 evaluable subjects, 10 presented an objective response. Of these 10 subjects, five showed a complete response and five presented a partial response. The remaining two subjects were stable under treatment. TG1042 was well tolerated. The most frequent adverse effects were moderate injection-site reactions and transient fever.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.